Built for speed. Proven at scale.
Start faster, scale globally, and act on data in real time with Agentic eCOA and a platform built to support the speed and scale needed for vaccine trials.
Launch faster. Stay on track. Make decisions earlier.
Start in weeks, not months
Achieve AI-powered rapid study builds and translations for tight startup windows without missing critical seasons.
Detect safety and efficacy signals in real time
Capture reactogenecity, immunogenecity, and potential adverse event data as they happen, not after the fact. Replace delayed batch reviews with real-time signal detection and daily data transfers.
Stand up new studies without rebuilding
Run studies across populations, regions, and regulatory requirements on a repeatable foundation built for your entire vaccine program.
Vaccine experience engineered for scale
vaccine studies completed on the Medable platform
participants enrolled globally across vaccine trials
countries supported across vaccine programs
Agentic workflows built for vaccine speed.
Study start up
Get from protocol to live study in weeks — not months. AI-assisted eCOA configuration, accelerated translation, and localization mean you're ready before the enrollment window closes.
POWERED BY AGENTIC ECOA
Inspection readiness
Stop scrambling before inspections. Automated daily document filing keeps your TMF current so audit readiness is the default state, not a last-minute push.
POWERED BY TMF AGENT
Site oversite and signal
Stay on top of enrollment and site performance — even at 50–1,000+ participants per day. Pre- and post-visit summaries generated automatically.
POWERED BY CLINICAL MONITORING AGENT
Signal detection and data quality
Catch risks before they compound. AI-driven data harmonization detects safety signals early and keeps decision-making ahead of the data curve.
POWERED BY CLINICAL MONITORING AGENT
%20(3).gif)
Build once, reuse across trials
Standardized templates, reactogenicity diaries, and reusable translations— 80% trial-ready from day one. Build new studies in as little as 4 weeks, not 4 months.
.webp)
Designed for vaccine science
Branching diary logic, cohort-aware phase-adaptive execution, and reactogenicity and immunogenicity capture aligned to regulatory guidance across diverse populations.
Every stakeholder, one platform
eCOA, eConsent, TeleVisit, caregiver workflows, and site tools unified under single sign-on. Purpose-built for healthy volunteers, caregivers, and site staff.
Case study: Scaling global vaccine mega-trials for a top-5 pharma
Learn how Medable enabled a top-5 pharma to scale vaccine mega-trials with near-100% enrollment, real-time safety data, and >90% diary compliance.
>90%
900+
48
50k+
The latest in vaccines
Medable enables over 90% eCOA adherence in vaccine trial
A leading biotech company came to Medable looking to conduct a vaccine trial. They were concerned that their trial’s participant population of persons aged 50+ years may be hesitant to use the sponsors’ chosen eCOAtrial technology, would not be engaged in the study, and therefore may not provide consistent trial data.
Learn how we drove success for them, including 90% eCOA adherence.
Bridging the gap: Ensuring sites are successful with Medable
For years, clinical research sites have been vocal about the technological challenges they face conducting trials. Obstacles such as multiple disparate systems per trial, an abundance of passwords, lack of interoperability, and other issues all showcase how technology can be as significant a hindrance as it is a boon. As a recent Forbes article suggests, if clinical research technology doesn’t empower sites, it risks slowing down the entire trial.
How we standardized deploying vaccine studies in five weeks
By Musaddiq Khan, VP, DCT Solutions
At Medable, we’re always looking to understand the changing environment of clinical research, and how we can help customers overcome the various challenges, risks, and scenarios that these changes bring.
For the past year, I, various clinicians, and research experts at Medable have been working closely to improve how we conduct research for various therapeutic areas. Much like the results shown in Tufts CSDD’s latest whitepaper, we believe that a well-thought, decentralized approach can help bring new therapies in historically challenging therapeutic areas to markets faster.
The result of this work is a brand-new decentralized approach we’re bringing to the market.
Frequently asked questions
With our “Core” vaccine offering you can deploy your trial in as little as 5 weeks from PDS to go-live.
Yes! Our platform provides real-time access to key safety data throughout your trial.
Yes. The need for rapid enrollment, changes in affected area, and need to remotely collect data are perfect for our pre-built solutions.
If it is a vaccine study, our offering is able to service your unique vaccine trial’s needs. Our SMEs can review protocol requirements and confirm it’s a good fit for our digital trial solutions.
The Vaccine offering is a pre-built, standardized solution that can be rapidly deployed and scaled across your portfolio.